Given the inhibition effects of miRNA-296-3p on tumors and the interaction of MSL2 and HBV, we assumed that miRNA-296-3p and MSL2 were involved in the procession of HCC. The gene discussed is MSL2; the disease is hepatocellular carcinoma.